SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D/A

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(a) AND
AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2(a)

(Amendment No. 17)^*

Reinsurance Group of America, Incorporated

(Name of Issuer)

Common Stock, Par Value $0.01 Per Share

(Title of Class of Securities)

759351604

(CUSIP Number)

Gwenn L. Carr
MetLife, Inc.
1095 Avenue of the Americas
New York, New York 10036
(212) 578-2211

November 25, 2008

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

          Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent.

          * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

          The information required on the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.		759351604		Page		2		of		9

* This percentage assumes that 72,559,315 shares of RGA common stock are issued and outstanding immediately following the Conversion, as described in Item 4 of this Schedule 13D Statement. As reported in the Proxy Statement furnished to RGA shareholders in connection with the special meeting of RGA shareholders to approve the Conversion, there were 33,080,776 shares of RGA class A common stock and 29,243,539 shares of RGA class B common stock issued and outstanding as of October 17, 2008. In addition, on November 4, 2008, RGA completed a public stock offering in which 10,235,000 shares of RGA class A common stock became issued and outstanding. Pursuant to the Conversion, all shares of RGA class B common stock were converted into shares of RGA class A common stock on a one-for-one basis. Such shares of RGA class A common stock were immediately thereafter redesignated as shares of RGA common stock.

CUSIP No.		759351604		Page		3		of		9

* This percentage assumes that 72,559,315 shares of RGA common stock are issued and outstanding immediately following the Conversion, as described in Item 4 of this Schedule 13D Statement. As reported in the Proxy Statement furnished to RGA shareholders in connection with the special meeting of RGA shareholders to approve the Conversion, there were 33,080,776 shares of RGA class A common stock and 29,243,539 shares of RGA class B common stock issued and outstanding as of October 17, 2008. In addition, on November 4, 2008, RGA completed a public stock offering in which 10,235,000 shares of RGA class A common stock became issued and outstanding. Pursuant to the Conversion, all shares of RGA class B common stock were converted into shares of RGA class A common stock on a one-for-one basis. Such shares of RGA class A common stock were immediately thereafter redesignated as shares of RGA common stock.

CUSIP No.		759351604		Page		4		of		9

* This percentage assumes that 72,559,315 shares of RGA common stock are issued and outstanding immediately following the Conversion, as described in Item 4 of this Schedule 13D Statement. As reported in the Proxy Statement furnished to RGA shareholders in connection with the special meeting of RGA shareholders to approve the Conversion, there were 33,080,776 shares of RGA class A common stock and 29,243,539 shares of RGA class B common stock issued and outstanding as of October 17, 2008. In addition, on November 4, 2008, RGA completed a public stock offering in which 10,235,000 shares of RGA class A common stock became issued and outstanding. Pursuant to the Conversion, all shares of RGA class B common stock were converted into shares of RGA class A common stock on a one-for-one basis. Such shares of RGA class A common stock were immediately thereafter redesignated as shares of RGA common stock.

CUSIP No.		759351604		Page		5		of		9

* This percentage assumes that 72,559,315 shares of RGA common stock are issued and outstanding immediately following the Conversion, as described in Item 4 of this Schedule 13D Statement. As reported in the Proxy Statement furnished to RGA shareholders in connection with the special meeting of RGA shareholders to approve the Conversion, there were 33,080,776 shares of RGA class A common stock and 29,243,539 shares of RGA class B common stock issued and outstanding as of October 17, 2008. In addition, on November 4, 2008, RGA completed a public stock offering in which 10,235,000 shares of RGA class A common stock became issued and outstanding. Pursuant to the Conversion, all shares of RGA class B common stock were converted into shares of RGA class A common stock on a one-for-one basis. Such shares of RGA class A common stock were immediately thereafter redesignated as shares of RGA common stock.

     This Amendment amends and supplements the Statement on Schedule 13D, as amended (the “Schedule 13D Statement”), relating to the shares of common stock, par value $0.01 per share, and related preferred stock purchase rights (collectively, the “RGA common stock”), of Reinsurance Group of America, Incorporated (“RGA” or the “Issuer”) previously filed by (i) MetLife, Inc. (“MLINC”), (ii) Metropolitan Life Insurance Company, a wholly owned subsidiary of MLINC (“MetLife”), (iii) GenAmerica Financial, LLC, a wholly owned subsidiary of MetLife (“GenAm Financial”) and (iv) General American Life Insurance Company, a wholly owned subsidiary of GenAm Financial (“GenAm Life” and collectively with MLINC, MetLife and GenAm Financial, the “Filing Parties”). This Amendment is being filed to update the Schedule 13D Statement in light of certain recent events. Capitalized terms used and not defined in this Amendment have the meanings set forth in the Schedule 13D Statement.

ITEM 1.		SECURITY AND ISSUER.

     Item 1 is hereby amended and restated as follows:

     “This Schedule 13D Statement relates to the RGA common stock. This class of equity securities was created in connection with the Conversion described in Item 4 of the Schedule 13D Statement, which was completed on November 25, 2008. The Schedule 13D Statement previously filed by the Filing Parties related to the shares of class A common stock, par value $0.01 per share, and related Series A-1 preferred stock purchase rights (collectively, the “RGA class A common stock”), of RGA that were issued and outstanding immediately prior to the completion of the Conversion. The principal executive offices of the Issuer are located at 1370 Timberlake Manor Parkway, Chesterfield, Missouri 63017.”

ITEM 4.		PURPOSE OF TRANSACTION.

     Item 4 is hereby amended by adding the following after the last paragraph thereof:

     “Following the Recapitalization and the Split-Off, which were each completed on September 12, 2008, the Filing Parties beneficially owned, and continued to own, 3,000,000 shares of RGA class A common stock. On November 25, 2008, RGA held a special meeting of its shareholders to consider, among other things, a proposal to convert RGA’s dual class common stock structure into a single class common stock structure (the “Conversion”). Pursuant to the Conversion, all issued and outstanding shares of class B common stock, par value $0.01 per share, and related Series B preferred stock purchase rights (“RGA class B common stock”), of RGA would be converted into shares of RGA class A common stock on a one-for-one basis. Following approval of the Conversion by the requisite number of RGA shareholders, the Conversion was completed on November 25, 2008 and, immediately thereafter, all shares of RGA class A common stock were redesignated as shares of RGA common stock. Following the Conversion, the Filing Parties beneficially own 3,000,000 shares of RGA common stock and although the Filing Parties have not acquired or disposed of any shares of RGA common stock, the percentage ownership of RGA common stock of the Filing Parties has changed as a result of the Conversion.”

ITEM 5.		INTEREST IN SECURITIES OF THE ISSUER.

     Item 5 is hereby amended by replacing the first sentence of the first paragraph of Item 5(a) and (b) with the following:

     “(a) and (b). As of November 25, 2008, each of the Filing Parties beneficially owned 3,000,000 shares of RGA common stock, which represents approximately 4.1% of the outstanding shares of RGA common stock. The other information contained in Item 4 of this Schedule 13D Statement is incorporated herein by reference.”

     Item 5 is hereby further amended by replacing the last paragraph of Item 5(a) and (b) with the following:

     “The percentage amounts set forth in Item 5 assume that 72,559,315 shares of RGA common stock are issued and outstanding immediately following the Conversion. As reported in the Proxy Statement furnished to RGA shareholders in connection with the special meeting of RGA shareholders to approve the Conversion, there were 33,080,776 shares of RGA class A common stock and 29,243,539 shares of RGA class B common stock issued and outstanding as of October 17, 2008. In addition, on November 4, 2008, RGA completed a public stock offering in which 10,235,000 shares of RGA class A common stock became issued and outstanding. Pursuant to the Conversion, all shares of RGA class B common stock were converted into shares of RGA class A common stock on a one-for-one basis. Such shares of RGA class A common stock were immediately thereafter redesignated as shares of RGA common stock.”

     Item 5 is hereby further amended by adding the following under Item 5(e):

     “After the completion of the Conversion, which occurred on November 25, 2008, the Filing Parties ceased to beneficially own more than five percent of the outstanding shares of RGA common stock and, as a result, are no longer required to be reporting persons under Section 13(d) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and the related rules promulgated thereunder. In light of the foregoing, the Filing Parties will no longer file a Schedule 13D Statement unless and until such time as they are required to be reporting persons under Section 13(d) of the Exchange Act or the related rules promulgated thereunder.”

ITEM 6.		CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO THE SECURITIES OF THE ISSUER.

     Item 6 is hereby amended by adding the following after the last paragraph:

     “The information set forth in Item 4 of this Schedule 13D Statement is incorporated herein by reference.”

ITEM 7.		MATERIAL TO BE FILED AS EXHIBITS.

     Item 7 is hereby amended by amending and supplementing the exhibits as follows:

Exhibit		Description of Exhibits
1		Directors and Executive Officers of the Filing Parties
9		Agreement Required for Joint Filing under Rule 13d-1(k)(1)

SIGNATURE

     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

November 25, 2008

EXHIBIT 1

Directors and Executive Officers of the Filing Parties

Set forth below is the name and present principal occupation or employment of each director and executive officer of MLINC and MetLife. MLINC is a holding company and MetLife is an insurance company. The principal business address of MLINC and MetLife is 200 Park Avenue, New York, NY 10166-0188. Unless otherwise noted, the business address of each of the directors and executive officers is c/o MetLife, Inc. Each person listed below is a citizen of the United States.

Directors

Name and Business Address		Principal Occupation or Employment
Sylvia Mathews Burwell The Bill and Melinda Gates Foundation 1551 Eastlake Avenue East Seattle, Washington 98102		President of the Global Development Program at the Bill and Melinda Gates Foundation
Eduardo Castro-Wright Wal-Mart Stores, Inc. 702 Southwest 8th St. Bentonville, AK 72716		President and Chief Executive Officer of Wal-Mart Stores, USA
Burton A. Dole, Jr.		Retired Chairman of Dole/Neal LLC (privately-held energy management firm), and retired Partner and Chief Executive Officer of MedSouth Therapy Associates, LLC (rehabilitative health care)
Cheryl W. Grise		Retired Executive Vice President of Northeast Utilities (public utility holding company)
C. Robert Henrikson		Chairman, President and Chief Executive Officer, MLINC and MetLife
R. Glenn Hubbard Dean’s Office Columbia Business School Uris Hall 3022 Broadway New York, New York 10027		Dean of the Graduate School of Business at Columbia University (business school)
John M. Keane 2020 K Street N.W. Suite 300 Washington, DC 20006		Co-Founder and Senior Managing Director of Keane Advisors, LLC (private equity investment firm)

Name and Business Address		Principal Occupation or Employment
James M. Kilts Centerview Partners Management, LLC 16 School St. Rye, NY 10580		Partner, Centerview Partners Management, LLC (financial advisory firm)
Hugh B. Price Brookings Institution 1775 Massachusetts Avenue, NW Washington, D.C. 20036		Senior Fellow, Brookings Institution
David Satcher Morehouse School of Medicine 720 Westview Drive SW Atlanta, Georgia 30310-1495		Director of the Satcher Health Leadership Institute and the Center of Excellence on Health Disparities at the Morehouse School of Medicine
Kenton J. Sicchitano		Retired Global Managing Partner of PricewaterhouseCoopers, LLP (assurance, tax and advisory services)
William C. Steere, Jr. Pfizer Inc. 235 East 42nd Street, 22nd Floor New York, New York 10017		Director and Retired Chairman of the Board and Chief Executive Officer of Pfizer Inc.
Lulu C. Wang Tupelo Capital Management LLC 12 E. 49th St. New York, NY 10017		Chief Executive Officer of Tupelo Capital Management, LLC

Executive Officers (who are not directors)

Name		Principal Occupation or Employment
Ruth A. Fattori		Executive Vice President and Chief Administrative Officer, MLINC and MetLife
Steven A. Kandarian		Executive Vice President and Chief Investment Officer, MLINC and MetLife
James L. Lipscomb		Executive Vice President and General Counsel, MLINC and MetLife
Maria R. Morris		Executive Vice President, Technology and Operations, MLINC and MetLife
William J. Mullaney		President, Institutional Business, MLINC and MetLife
William J. Toppeta		President, International, MLINC and MetLife
Lisa M. Weber		President, Individual Business, MLINC and MetLife
William J. Wheeler		Executive Vice President and Chief Financial Officer, MLINC and MetLife

GenAm Financial is a holding company. The principal business address of GenAm Financial is One MetLife Plaza, 27-01 Queens Plaza North, Long Island City, New York 11101. GenAm Financial is a limited liability company with MetLife serving as its Manager. The directors and executive officers of MetLife are listed above.

Set forth below is the name and present principal occupation or employment of each director and executive officer of GenAm Life. GenAm Life is an insurance company. The principal business address of GenAm Life is 13045 Tesson Ferry Road, St. Louis, Missouri 63128. Unless otherwise noted, the business address for each of the directors and executive officers is c/o MetLife, Inc. Each person listed below is a citizen of the United States.

Name and Business Address		Principal Occupation or Employment
Michael K. Farrell 10 Park Avenue Morristown, New Jersey 07962		Executive Vice President, MetLife; Director, GenAm Life
Ruth A. Fattori		Executive Vice President and Chief Administrative Officer, MLINC and MetLife; Director, GenAm Life
James L. Lipscomb		Executive Vice President and General Counsel, MLINC and MetLife; Director, GenAm Life
William J. Mullaney		President, Institutional Business, MLINC and MetLife; Director, GenAm Life
Joseph J. Prochaska, Jr.		Executive Vice President and Chief Accounting Officer, MLINC, MetLife and GenAm Life
Eric T. Steigerwalt		Senior Vice President and Treasurer, MLINC, MetLife and GenAm Life; Director, GenAm Life
Stanley J. Talbi		Executive Vice President, MetLife; Director, GenAm Life
Michael J. Vietri		Executive Vice President, MetLife; Director, GenAm Life
Lisa M. Weber		President, Individual Business, MLINC and MetLife; Chairman of the Board, President, Chief Executive Officer and Director, GenAm Life
William J. Wheeler		Executive Vice President and Chief Financial Officer, MLINC and MetLife; Director, GenAm Life

EXHIBIT 9

Joint Filing Agreement

In accordance with Rule 13d-1(k)(1) of Regulation 13D-G of the Securities Exchange Act of 1934, the persons or entities below agree to the joint filing on behalf of each of them of the Statement on Schedule 13D (including any and all amendments thereto) with respect to the Common Stock of Reinsurance Group of America, Incorporated, and agree that such statement is, and any amendments thereto filed by any of them will be, filed on behalf of each of them, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.

Dated: November 25, 2008